FeesSafety
Pluang+

Mammoth Energy rated B- with 21% upside; pivots to aviation engine leasing amid credit risks.

Analyst Insights
03 Nov 2026, 12:36 WIB
Seeking Alpha
View Source
Bullish
Mammoth Energy rated B- with 21% upside; pivots to aviation engine leasing amid credit risks.

Mammoth Energy (TUSK) received a B- rating with a 12-month price target of $3.85, suggesting a 21.1% upside from its current price of $3.18. The company’s shift to aviation leasing, focusing mainly on engines and auxiliary power units (APUs), sets it apart from typical aircraft lessors, with these assets accounting for 85% of its aviation revenue. However, there is notable credit risk due to the financial uncertainty of lessee Surf Air. Despite this, high lease yields of 18% provide some compensation for the risk. Key upcoming catalysts include deploying 15 idle assets, resolving a $42.3 million tax liability in Puerto Rico, and improving lessee transparency for better risk assessment.

Mammoth Energy stock is the subject of recent analysis, and here is relevant market data for context. For readers following the Industrials sector, as of Nov 03, 2026 16:11 WIB, out of 135 priced US Industrials stocks tradable on Pluang, 67 rose and 56 fell. Notable movers include Canadian National Railway Co. (CNI) at USD 123.84 with a 2.32% decline and a typical hold time of 105 days, Frontline Plc (FRO) at USD 53.22 with a 2.19% gain and a typical hold time of 9 days, and Old Dominion Freight Line Inc (ODFL) at USD 173.10 with a 1.78% decline and a typical hold time of 77 days. Pluang order activity shows heavy selling for CNI (84% Sell) and full buying for FRO and ODFL (100% Buy).

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App